Article
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Neutral
0.0
−100 Bearish
0
+100 Bullish
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This